(Q81004098)
English
Gemtuzumab ozogamicin (Mylotarg) as single-agent treatment for frail patients 61 years of age and older with acute myeloid leukemia: final results of AML-15B, a phase 2 study of the European Organisation for Research and Treatment of Cancer and Grup
scientific article published on 01 October 2005
Statements
Gemtuzumab ozogamicin (Mylotarg) as single-agent treatment for frail patients 61 years of age and older with acute myeloid leukemia: final results of AML-15B, a phase 2 study of the European Organisation for Research and Treatment of Cancer and Gruppo Italiano Malattie Ematologiche dell'Adulto Leukemia Groups (English)
S Suciu
R Stasi
R Willemze
F Mandelli
D Selleslag
C Denzlinger
P Muus
R Stauder
Z Berneman
J Pruijt
F Nobile
V Cassibba
J-P Marie
F Beeldens
L Baila